FeesSafety
Pluang+

U.S. spot Solana ETFs see no net flow change, holding steady at $0 million on Nov 18

Market News
19 Nov 2026, 03:38 WIB
Tokenpost
View Source
Neutral
U.S. spot Solana ETFs see no net flow change, holding steady at $0 million on Nov 18

On November 18, U.S. spot Solana (SOL) ETFs experienced no net inflows or outflows, maintaining a flat net flow of $0.0 million, consistent with the previous day. All seven listed Solana ETFs—BSOL, VSOL, FSOL, TSOL, SOEZ, MSOL, and GSOL—reported no changes in fund flows. Over the past five trading sessions, these ETFs have accumulated net inflows totaling $6.7 million, with total net flows since their launch reaching $1.415 billion. This stability indicates steady investor interest in Solana ETFs without recent volatility in fund movements.

The U.S. spot Solana ETFs recorded net flows of $0.0 million on November 18, maintaining stability in fund movements. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 19, 2026 08:21 WIB: out of 50 priced cryptocurrencies, 8 rose and 40 fell. Notable movers include XNO (Nano) with a 1-day change of +3.72% and Pluang order activity of 45% Sell / 55% Buy, NEO (Neo) down 3.34% with 96% Sell / 4% Buy, and AVAX (Avalanche) down 3.08% with 6% Sell / 94% Buy.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App